ELI LILLY & CO

Inside Eli Lilly’s recent insider sell‑off, Executive VP Seymour Melissa trades 17 shares—routine portfolio moves amid growing women’s health and GLP‑1 bets that keep the stock’s outlook bullish.

Insight into Eli Lilly insider buying: EVP Seymour Melissa’s recent 981‑share purchase signals long‑term confidence ahead of earnings and pipeline growth.

How Eli Lilly’s endowment sale in a bull market signals disciplined liquidity and growth‑driven strategy—why investors should stay tuned.

Insider buying at Eli Lilly signals confidence in its $7B Kelonia Therapeutics acquisition, suggesting a bullish outlook for investors.

Insider buying at Eli Lilly shows leadership confidence amid a falling share price. Learn why Yuffa Ilya’s 3,394‑share purchase could signal undervaluation and boost long‑term investors.

Explore how Eli Lilly’s executive buys—especially Van Naarden Jacob’s recent trade—signal insider confidence, market trends, and future growth prospects.

Insider selling at Eli Lilly: LILLY ENDOWMENT INC liquidated $95 m of shares amid a 35.6% rally, signaling routine portfolio rotation rather than a confidence hit.